加拿大暂停向55岁以下人士接种阿斯利康疫苗
加拿大卫生官员表示,将停止向55岁以下的人士接种阿斯利康(AZN.US)疫苗。
此前欧洲多国多宗接种阿斯利康疫苗後,出现血栓塞等严重不良反应个案,并主要集中在年轻女性。目前加拿大为民众接种超过30万剂阿斯利康疫苗,并无收到类此的不良反应报告。
加拿大当局表示,暂时停止为55岁以下成年人士接种是审慎的做法,因为加拿大有替代疫苗可使用,到目前为止加拿大大部分的疫苗供应是来自辉瑞及Moderna。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.